Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$0.8 - $1.15 $377,508 - $542,667
-471,885 Closed
0 $0
Q2 2021

Aug 16, 2021

SELL
$1.02 - $1.52 $1.55 Million - $2.31 Million
-1,520,296 Reduced 76.31%
471,885 $500,000
Q1 2021

May 18, 2021

BUY
$1.0 - $3.0 $1.99 Million - $5.98 Million
1,992,181 New
1,992,181 $2.95 Million

About Salarius Pharmaceuticals, Inc.


  • Ticker SLRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,244,650
  • Market Cap $3.37M
  • Description
  • Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a ...
More about SLRX
Track This Portfolio

Track Silverarc Capital Management, LLC Portfolio

Follow Silverarc Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Silverarc Capital Management, LLC with notifications on news.